AstraZeneca plc (AZN) Shares Sold by Raymond James Trust N.A.

Raymond James Trust N.A. reduced its stake in shares of AstraZeneca plc (NYSE:AZN) by 15.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 54,681 shares of the company’s stock after selling 10,165 shares during the period. Raymond James Trust N.A.’s holdings in AstraZeneca were worth $2,164,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. FMR LLC raised its holdings in AstraZeneca by 35.2% during the 2nd quarter. FMR LLC now owns 20,243,181 shares of the company’s stock worth $710,738,000 after buying an additional 5,272,590 shares during the period. Jennison Associates LLC acquired a new stake in shares of AstraZeneca in the second quarter valued at approximately $676,716,000. Fisher Asset Management LLC raised its holdings in shares of AstraZeneca by 4.3% in the second quarter. Fisher Asset Management LLC now owns 13,079,941 shares of the company’s stock valued at $459,237,000 after purchasing an additional 535,782 shares during the last quarter. Northern Trust Corp raised its holdings in shares of AstraZeneca by 45.2% in the second quarter. Northern Trust Corp now owns 3,467,814 shares of the company’s stock valued at $121,755,000 after purchasing an additional 1,079,790 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of AstraZeneca by 53.6% in the first quarter. Millennium Management LLC now owns 2,152,762 shares of the company’s stock valued at $75,282,000 after purchasing an additional 751,610 shares during the last quarter. Hedge funds and other institutional investors own 15.97% of the company’s stock.

A number of analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, June 29th. Guggenheim assumed coverage on shares of AstraZeneca in a report on Monday, October 8th. They issued a “buy” rating on the stock. ValuEngine upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Saturday, July 28th. Finally, Jefferies Financial Group downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $39.78.

In other news, major shareholder Plc Astrazeneca bought 246,666 shares of the stock in a transaction that occurred on Friday, September 28th. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $3,699,990.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

NYSE AZN opened at $39.08 on Wednesday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.54 and a current ratio of 0.72. AstraZeneca plc has a 12-month low of $31.99 and a 12-month high of $40.16. The company has a market capitalization of $100.23 billion, a PE ratio of 9.13, a price-to-earnings-growth ratio of 2.10 and a beta of 0.58.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 26th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.38. AstraZeneca had a net margin of 11.98% and a return on equity of 29.89%. The company had revenue of $5.16 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same period last year, the company earned $0.87 earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. On average, analysts predict that AstraZeneca plc will post 1.68 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: How accurate is the Rule of 72?

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply